The goal at the Center for Synthetic Immunity is to develop novel therapeutics and move them into the clinic.

We are always interested in discussing possible collaborations for scientific and development projects with potential academic, industry, and financial partners. 

Current Industry Partners

• Celdara Medical LLC for the development of the NKG2D, NKp30, and B7H6 based CARs. This work is conducted in compliance with the policies of Dartmouth College.
  
  
• Celyad (formerly Cardio3 Biosciences) has acquired OnCyte, a suite of NK receptor based CARs, from Celdara Medical. Read more about this acquisition in Genetic Engineering & Biotechnology News. 
  
  

Licensing, Partnering, Support and Other Opportunities:

As CSI develops novel therapeutics and platform technologies, some of them can be read about on these web pages. New projects will be described in more detail as they mature. The team welcomes  novel project ideas for collaboration.

If you would like more information about the ongoing research or career opportunities at the Center for Synthetic Immunity, please contact us.

For licensing, partnering, philanthropic support, or other opportunities to work with the CSI research team, please contact us via e-mail at Synthetic.Immunity@dartmouth.edu or by phone at 603-650-8675.